Pancreatic cancer (English Wikipedia)

Harris RE (2013). "Epidemiology of pancreatic cancer". Epidemiology of Chronic Disease. Jones & Bartlett. pp. 181–190. ISBN 978-0-7637-8047-0. Archived from the original on 24 June 2016.
Handbook of Pancreatic Cancer. New York: Springer. 2009. p. 288. ISBN 978-0-387-77497-8. Archived from the original on 10 September 2017. Retrieved 12 June 2016.

cancer.gov

"Pancreatic Cancer Treatment (PDQ®) Patient Version". National Cancer Institute. National Institutes of Health. 17 April 2014. Archived from the original on 5 July 2014. Retrieved 8 June 2014.
"What Is Cancer? Defining Cancer". National Cancer Institute, National Institutes of Health. 7 March 2014. Archived from the original on 25 June 2014. Retrieved 5 December 2014.
"Pancreatic Cancer Treatment (PDQ®) Health Professional Version". National Cancer Institute. National Institutes of Health. 21 February 2014. Archived from the original on 22 October 2014. Retrieved 24 November 2014. "The highest cure rate occurs if the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. In cases with localized disease and small cancers (<2 cm) with no lymph-node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is still associated with a low actuarial five-year survival rate of 18% to 24%."
National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) Incidence and Mortality "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version". Archived from the original on 4 January 2015. Retrieved 29 December 2014.
"Cancer Drug Information: FDA Approval for Erlotinib Hydrochloride". National Cancer Institute. National Institutes of Health. 3 July 2013. Archived from the original on 29 November 2014. Retrieved 5 December 2014.
Everolimus Approved for Pancreatic Neuroendocrine Tumors Archived 16 July 2016 at the Wayback Machine The ASCO Post. 15 May 2011, Volume 2, Issue 8
National Cancer Institute. Cancer Drug Information. FDA Approval for Sunitinib Malate Archived 5 January 2015 at the Wayback Machine. Pancreatic Neuroendocrine Tumors

seer.cancer.gov

"Pancreatic Cancer – Cancer Stat Facts". SEER. Retrieved 4 April 2019.

cancer.org

"Can pancreatic cancer be prevented?". American Cancer Society. 11 June 2014. Archived from the original on 13 November 2014. Retrieved 13 November 2014.
"Cancer Facts and Figures 2014" (PDF). American Cancer Society. Archived (PDF) from the original on 18 December 2014. Retrieved 5 January 2015., p. 19, "Though evidence is still accumulating, consumption of red or processed meat, or meat cooked at very high temperatures, may slightly increase risk."
"Staging of pancreatic cancer". American Cancer Society. 11 June 2014. Archived from the original on 10 August 2020. Retrieved 29 September 2014.
"Diet and activity factors that affect risks for certain cancers: Pancreatic cancer section". American Cancer Society. 20 August 2012. Archived from the original on 4 November 2014. Retrieved 4 November 2014.
"Palliative or Supportive Care". American Cancer Society. 2014. Archived from the original on 21 August 2014. Retrieved 20 August 2014.
"If treatment for pancreatic cancer stops working". American Cancer Society. 11 June 2014. Archived from the original on 22 October 2014. Retrieved 20 August 2014.
"Cancer Facts and Figures 2014" (PDF). American Cancer Society. Archived (PDF) from the original on 18 December 2014. Retrieved 5 January 2015., Table, p. 18, rates adjusted for normal life expectancy
"What are the key statistics about pancreatic cancer?". American Cancer Society. 11 June 2014. Archived from the original on 11 November 2014. Retrieved 11 November 2014.
"What's new in pancreatic cancer research and treatment?". American Cancer Society. 2019. Retrieved 2 May 2019.

cancernetwork.com

Text is available electronically (but may require free registration) See: Benson AB, Myerson RJ, Sasson AR (2010). Pancreatic, neuroendocrine GI, and adrenal cancers. Cancer Management: A Multidisciplinary Approach (13th ed.). UBM Medica. ISBN 978-0-615-41824-7. Archived from the original on 15 May 2011.

cancerresearchuk.org

"Pancreatic cancer statistics". Cancer Research UK. Archived from the original on 18 December 2014. Retrieved 18 December 2014.; "In 2010, in the UK, the lifetime risk of developing pancreatic cancer is 1 in 73 for men and 1 in 74 for women", noting "The lifetime risk ... has been calculated ... using the 'Current Probability' method; this is a different method used from most other cancer sites since the possibility of having more than one diagnosis of pancreatic cancer over the course of their lifetime is very low"
"Pancreatic cancer research". Cancer Research UK. Archived from the original on 18 February 2014. Retrieved 17 July 2014.

cancerstaging.org

"Chapter 15; Pancreas" (PDF). Manual for Staging of Cancer (2nd ed.). American Joint Committee on Cancer. pp. 95–98. Archived (PDF) from the original on 29 November 2014. See p. 95 for citation regarding "... lesser degree of involvement of bones and brain and other anatomical sites."

cbsnews.com

"Vaccine targeting pancreatic cancer shows promise in new study of clinical trial - CBS News". www.cbsnews.com. 19 February 2025. Retrieved 21 February 2025.

clinicaltrialsregister.eu

"Clinical Trials Register". www.clinicaltrialsregister.eu. Retrieved 26 January 2025.

creativecommons.org

Venturi S (August 2021). "Cesium in Biology, Pancreatic Cancer, and Controversy in High and Low Radiation Exposure Damage-Scientific, Environmental, Geopolitical, and Economic Aspects". International Journal of Environmental Research and Public Health. 18 (17): 8934. doi:10.3390/ijerph18178934. PMC 8431133. PMID 34501532. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA (June 2016). "Surgical and molecular pathology of pancreatic neoplasms". Diagnostic Pathology. 11 (1): 47. doi:10.1186/s13000-016-0497-z. PMC 4897815. PMID 27267993. (distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)), Image title and optimization: Mikael Häggström, M.D.

doi.org

Ryan DP, Hong TS, Bardeesy N (September 2014). "Pancreatic adenocarcinoma". The New England Journal of Medicine. 371 (11): 1039–49. doi:10.1056/NEJMra1404198. PMID 25207767.
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. (September 2013). "Recent progress in pancreatic cancer". CA: A Cancer Journal for Clinicians. 63 (5): 318–48. doi:10.3322/caac.21190. PMC 3769458. PMID 23856911.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer" (PDF). Lancet. 378 (9791): 607–20. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466. Archived from the original (PDF) on 12 January 2015.
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Bond-Smith G, Banga N, Hammond TM, Imber CJ (May 2012). "Pancreatic adenocarcinoma". BMJ. 344 (may16 1): e2476. doi:10.1136/bmj.e2476. PMID 22592847. S2CID 206894869.
Amri F, Belkhayat C, Yeznasni A, Koulali H, Jabi R, Zazour A, et al. (September 2023). "Association between pancreatic cancer and diabetes: insights from a retrospective cohort study". BMC Cancer. 23 (1): 856. doi:10.1186/s12885-023-11344-w. PMC 10496157. PMID 37697301.
Sun Y, He X, Sun Y (27 September 2023). "Red and processed meat and pancreatic cancer risk: a meta-analysis". Frontiers in Nutrition. 10: 1249407. doi:10.3389/fnut.2023.1249407. PMC 10565855. PMID 37829734.
Larsson SC, Wolk A (January 2012). "Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies". British Journal of Cancer. 106 (3): 603–607. doi:10.1038/bjc.2011.585. PMC 3273353. PMID 22240790.
Rohrmann S, Linseisen J, Nöthlings U, Overvad K, Egeberg R, Tjønneland A, et al. (February 2013). "Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition". International Journal of Cancer. 132 (3): 617–624. doi:10.1002/ijc.27637. PMID 22610753. S2CID 2613568.
Bardou M, Le Ray I (December 2013). "Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies". Best Practice & Research. Clinical Gastroenterology. 27 (6): 881–892. doi:10.1016/j.bpg.2013.09.006. PMID 24182608.
Wang Y, Miller FH, Chen ZE, Merrick L, Mortele KJ, Hoff FL, et al. (2011). "Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas". Radiographics. 31 (3): E47 – E64. doi:10.1148/rg.313105174. PMID 21721197.
Öberg K, Knigge U, Kwekkeboom D, Perren A, et al. (ESMO Guidelines Working Group) (October 2012). "Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii124 – vii130. doi:10.1093/annonc/mds295. PMID 22997445. (Table 5 outlines the proposed TNM staging system for PanNETs.)
Farrell JJ, Fernández-del Castillo C (June 2013). "Pancreatic cystic neoplasms: management and unanswered questions". Gastroenterology. 144 (6): 1303–15. doi:10.1053/j.gastro.2013.01.073. PMID 23622140.
The PanNET denomination is in line with WHO guidelines for the classification of tumors of the digestive system "WHO classification of tumours of the digestive system – NLM Catalog – NCBI". Archived from the original on 9 September 2017. Retrieved 7 September 2017. published in 2010. Historically, PanNETs have also been referred to by a variety of terms, and are still commonly called "pancreatic endocrine tumors". See: Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–12. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
Pannala R, Basu A, Petersen GM, Chari ST (January 2009). "New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer". The Lancet. Oncology. 10 (1): 88–95. doi:10.1016/S1470-2045(08)70337-1. PMC 2795483. PMID 19111249.
Sperti C, Moletta L, Patanè G (October 2014). "Metastatic tumors to the pancreas: The role of surgery". World Journal of Gastrointestinal Oncology. 6 (10): 381–92. doi:10.4251/wjgo.v6.i10.381. PMC 4197429. PMID 25320654.
Anderson LN, Cotterchio M, Gallinger S (August 2009). "Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada". Cancer Causes & Control. 20 (6): 825–834. doi:10.1007/s10552-009-9303-5. PMC 3907069. PMID 19194662.
Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. (July 2012). "Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)". Annals of Oncology. 23 (7): 1880–88. doi:10.1093/annonc/mdr541. PMC 3387822. PMID 22104574.
De Rubeis V, Cotterchio M, Smith BT, Griffith LE, Borgida A, Gallinger S, et al. (September 2019). "Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada". Cancer Causes & Control. 30 (9): 955–966. doi:10.1007/s10552-019-01197-9. PMC 6685923. PMID 31230151.
Peters ML, Tseng JF, Miksad RA (July 2016). "Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment". Clinical Therapeutics. 38 (7): 1622–35. doi:10.1016/j.clinthera.2016.03.006. PMID 27041411.
Reznik R, Hendifar AE, Tuli R (2014). "Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma". Frontiers in Physiology. 5: 87. doi:10.3389/fphys.2014.00087. PMC 3939680. PMID 24624093.
Greenhalf W, Grocock C, Harcus M, Neoptolemos J (May 2009). "Screening of high-risk families for pancreatic cancer". Pancreatology. 9 (3): 215–22. doi:10.1159/000210262. PMID 19349734. S2CID 29100310.
Venturi S (August 2021). "Cesium in Biology, Pancreatic Cancer, and Controversy in High and Low Radiation Exposure Damage-Scientific, Environmental, Geopolitical, and Economic Aspects". International Journal of Environmental Research and Public Health. 18 (17): 8934. doi:10.3390/ijerph18178934. PMC 8431133. PMID 34501532. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA (June 2016). "Surgical and molecular pathology of pancreatic neoplasms". Diagnostic Pathology. 11 (1): 47. doi:10.1186/s13000-016-0497-z. PMC 4897815. PMID 27267993. (distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)), Image title and optimization: Mikael Häggström, M.D.
Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, et al. (March 2011). "Genetic and epigenetic alterations in pancreatic carcinogenesis". Current Genomics. 12 (1): 15–24. doi:10.2174/138920211794520132. PMC 3129039. PMID 21886451.
Rooney SL, Shi J (October 2016). "Intraductal Tubulopapillary Neoplasm of the Pancreas: An Update From a Pathologist's Perspective". Archives of Pathology & Laboratory Medicine. 140 (10): 1068–73. doi:10.5858/arpa.2016-0207-RA. PMID 27684978.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. (August 2017). "A pathology atlas of the human cancer transcriptome". Science. 357 (6352): eaan2507. doi:10.1126/science.aan2507. PMID 28818916.
Park W, Chawla A, O'Reilly EM (7 September 2021). "Pancreatic Cancer: A Review". JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027. PMC 9363152. PMID 34547082.
Lewis MA, Yao JC (February 2014). "Molecular pathology and genetics of gastrointestinal neuroendocrine tumours". Current Opinion in Endocrinology, Diabetes and Obesity. 21 (1): 22–27. doi:10.1097/MED.0000000000000033. PMID 24310147. S2CID 31094880.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. (September 2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". The Journal of Clinical Endocrinology and Metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327.
Fitzgerald JE, White MJ, Lobo DN (April 2009). "Courvoisier's gallbladder: law or sign?". World Journal of Surgery. 33 (4): 886–91. doi:10.1007/s00268-008-9908-y. PMID 19190960. S2CID 21799234.
Piraka C, Scheiman JM (September 2011). "New diagnostic imaging modalities for pancreatic disease". Current Opinion in Gastroenterology. 27 (5): 475–80. doi:10.1097/MOG.0b013e328349e30c. PMID 21743318. S2CID 38963685.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P (October 2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii33–40. doi:10.1093/annonc/mds224. PMID 22997452.
Skafida E, Grammatoglou X, Glava C, Zissis D, Paschalidis N, Katsamagkou E, et al. (February 2010). "Adenosquamous carcinoma of the pancreas: a case report". Cases Journal. 3 (1): 41. doi:10.1186/1757-1626-3-41. PMC 2825199. PMID 20205828.
Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. (January 2016). "Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting". Annals of Surgery. 263 (1): 162–77. doi:10.1097/SLA.0000000000001173. PMC 4568174. PMID 25775066.
Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas Jr J (2017). "KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer". Cancers. 9 (5): 3956–3972. doi:10.3390/cancers9050042. PMC 5448143. PMID 28471481.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Cascinu S, Falconi M, Valentini V, Jelic S (May 2010). "Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 21 (Supplement 5): v55–58. doi:10.1093/annonc/mdq165. PMID 20555103.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (August 2019). "Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement". JAMA. 322 (5): 438–44. doi:10.1001/jama.2019.10232. PMID 31386141.
He XY, Yuan YZ (August 2014). "Advances in pancreatic cancer research: moving towards early detection". World Journal of Gastroenterology. 20 (32): 11241–48. doi:10.3748/wjg.v20.i32.11241. PMC 4145762. PMID 25170208.
Okano K, Suzuki Y (August 2014). "Strategies for early detection of resectable pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11230–40. doi:10.3748/wjg.v20.i32.11230. PMC 4145761. PMID 25170207.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. (January 2020). "Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium". Gut. 69 (1): 7–17. doi:10.1136/gutjnl-2019-319352. PMC 7295005. PMID 31672839.
Sun J, Li Y, Liu L, Jiang Z, Liu G (December 2019). "Aspirin use and pancreatic cancer risk: A systematic review of observational studies". Medicine. 98 (51): e18033. doi:10.1097/MD.0000000000018033. PMC 6940047. PMID 31860953.
Gurusamy KS, Kumar S, Davidson BR, Fusai G (February 2014). "Resection versus other treatments for locally advanced pancreatic cancer". The Cochrane Database of Systematic Reviews. 2014 (2): CD010244. doi:10.1002/14651858.CD010244.pub2. PMC 11095847. PMID 24578248.
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, et al. (December 2011). "Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis". Annals of Surgery. 254 (6): 882–93. doi:10.1097/SLA.0b013e31823ac299. PMID 22064622. S2CID 42685174.
Alamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, et al. (October 2014). "Improving outcomes in pancreatic cancer: key points in perioperative management". World Journal of Gastroenterology. 20 (39): 14237–45. doi:10.3748/wjg.v20.i39.14237. PMC 4202352. PMID 25339810.
Lopez NE, Prendergast C, Lowy AM (August 2014). "Borderline resectable pancreatic cancer: definitions and management". World Journal of Gastroenterology. 20 (31): 10740–51. doi:10.3748/wjg.v20.i31.10740. PMC 4138454. PMID 25152577.
Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M (July 2014). "Neoadjuvant strategies for pancreatic cancer". World Journal of Gastroenterology. 20 (28): 9374–83. doi:10.3748/wjg.v20.i28.9374 (inactive 1 November 2024). PMC 4110569. PMID 25071332.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (April 2010). "Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages". PLOS Medicine. 7 (4): e1000267. doi:10.1371/journal.pmed.1000267. PMC 2857873. PMID 20422030.
Christians KK, Evans DB (June 2015). "Additional support for neoadjuvant therapy in the management of pancreatic cancer". Annals of Surgical Oncology. 22 (6): 1755–58. doi:10.1245/s10434-014-4307-0. PMID 25519932.
Tsvetkova EV, Asmis TR (August 2014). "Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?". Current Oncology. 21 (4): e650–7. doi:10.3747/co.21.2006. PMC 4117630. PMID 25089113.
Zhan HX, Xu JW, Wu D, Zhang TP, Hu SY (February 2015). "Pancreatic cancer stem cells: new insight into a stubborn disease". Cancer Letters. 357 (2): 429–37. doi:10.1016/j.canlet.2014.12.004. PMID 25499079.
Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, et al. (August 2014). "Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics". World Journal of Gastroenterology. 20 (31): 10790–801. doi:10.3748/wjg.v20.i31.10790. PMC 4138459. PMID 25152582.
Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR (July 2016). "Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer". The Cochrane Database of Systematic Reviews. 2016 (7): CD009323. doi:10.1002/14651858.CD009323.pub3. PMC 6458011. PMID 27383694.
Heinemann V, Haas M, Boeck S (October 2013). "Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer". Annals of Oncology. 24 (10): 2484–92. doi:10.1093/annonc/mdt239. PMID 23852311.
Borazanci E, Von Hoff DD (September 2014). "Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer". Expert Review of Gastroenterology & Hepatology. 8 (7): 739–47. doi:10.1586/17474124.2014.925799. PMID 24882381. S2CID 31633898.
Haggstrom L, Chan WY, Nagrial A, Chantrill LA, Sim HW, Yip D, et al. (5 December 2024). "Chemotherapy and radiotherapy for advanced pancreatic cancer". The Cochrane Database of Systematic Reviews. 12 (12:CD011044). John Wiley & Sons, Ltd.: Abstract. doi:10.1002/14651858.CD011044.pub3. PMC 11619003. PMID 39635901.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. (November 2001). "Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial". Lancet. 358 (9293): 1576–1585. doi:10.1016/S0140-6736(01)06651-X. PMID 11716884. S2CID 23803289.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. (March 2004). "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer". The New England Journal of Medicine. 350 (12): 1200–1210. doi:10.1056/NEJMoa032295. PMID 15028824.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. (19 February 2025). "RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer". Nature: 1–10. doi:10.1038/s41586-024-08508-4. ISSN 1476-4687.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. (2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors". Neuroendocrinology. 95 (2): 120–34. doi:10.1159/000335587. PMID 22261872. S2CID 6985904.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. (2012). "ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary". Neuroendocrinology. 95 (2): 157–76. doi:10.1159/000335597. PMID 22262022. S2CID 2097604.
Rossi RE, Massironi S, Conte D, Peracchi M (January 2014). "Therapy for metastatic pancreatic neuroendocrine tumors". Annals of Translational Medicine. 2 (1): 8. doi:10.3978/j.issn.2305-5839.2013.03.01. PMC 4200651. PMID 25332984.
Gulenchyn KY, Yao X, Asa SL, Singh S, Law C (May 2012). "Radionuclide therapy in neuroendocrine tumours: a systematic review". Clinical Oncology. 24 (4): 294–308. doi:10.1016/j.clon.2011.12.003. PMID 22221516.
Vinik AI (November 2014). "Advances in diagnosis and treatment of pancreatic neuroendocrine tumors". Endocrine Practice. 20 (11): 1222–30. doi:10.4158/EP14373.RA. PMID 25297671.
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. (March 2010). "Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors". Seminars in Nuclear Medicine. 40 (2): 78–88. doi:10.1053/j.semnuclmed.2009.10.004. PMID 20113677.
Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, et al. (August 2014). "Peptide receptor radionuclide therapy for advanced neuroendocrine tumors". Thoracic Surgery Clinics. 24 (3): 333–49. doi:10.1016/j.thorsurg.2014.04.005. hdl:11392/2378236. PMID 25065935.
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, et al. (June 2015). "Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors". Cancer Chemotherapy and Pharmacology. 75 (6): 1099–114. doi:10.1007/s00280-014-2642-2. PMID 25480314. S2CID 39434924.
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, et al. (August 2015). "Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group". Annals of Surgical Oncology. 22 (8): 2685–99. doi:10.1245/s10434-014-4145-0. PMID 25366583. S2CID 8129133.
Buanes TA (August 2014). "Pancreatic cancer-improved care achievable". World Journal of Gastroenterology. 20 (30): 10405–18. doi:10.3748/wjg.v20.i30.10405. PMC 4130847. PMID 25132756.
Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA (March 2011). Arcidiacono PG (ed.). "Celiac plexus block for pancreatic cancer pain in adults". The Cochrane Database of Systematic Reviews. 2019 (3): CD007519. doi:10.1002/14651858.CD007519.pub2. PMC 6464722. PMID 21412903.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007). "Cancer statistics, 2007". CA: A Cancer Journal for Clinicians. 57 (1): 43–66. doi:10.3322/canjclin.57.1.43. PMID 17237035. S2CID 22305510.
Busnardo AC, DiDio LJ, Tidrick RT, Thomford NR (November 1983). "History of the pancreas". American Journal of Surgery. 146 (5): 539–50. doi:10.1016/0002-9610(83)90286-6. PMID 6356946.
Are C, Dhir M, Ravipati L (June 2011). "History of pancreaticoduodenectomy: early misconceptions, initial milestones and the pioneers". HPB. 13 (6): 377–84. doi:10.1111/j.1477-2574.2011.00305.x. PMC 3103093. PMID 21609369.
Cameron JL, Riall TS, Coleman J, Belcher KA (July 2006). "One thousand consecutive pancreaticoduodenectomies". Annals of Surgery. 244 (1): 10–5. doi:10.1097/01.sla.0000217673.04165.ea. PMC 1570590. PMID 16794383.
Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, et al. (September 2012). "Evolution of the Whipple procedure at the Massachusetts General Hospital". Surgery. 152 (3 Suppl 1): S56-63. doi:10.1016/j.surg.2012.05.022. PMC 3806095. PMID 22770961.
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. (November 2012). "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes". Nature. 491 (7424): 399–405. Bibcode:2012Natur.491..399.. doi:10.1038/nature11547. PMC 3530898. PMID 23103869.
Feng HY, Chen YC (September 2016). "Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective". World Journal of Gastroenterology. 22 (33): 7463–7477. doi:10.3748/wjg.v22.i33.7463. PMC 5011662. PMID 27672269.
Sharma B, Twelker K, Nguyen C, Ellis S, Bhatia ND, Kuschner Z, et al. (June 2024). "Bile Acids in Pancreatic Carcinogenesis". Metabolites. 14 (7): 348. doi:10.3390/metabo14070348. PMC 11278541. PMID 39057671.
Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV (September 2015). "Pancreatic cancer genomics: where can the science take us?". Clinical Genetics. 88 (3): 213–9. doi:10.1111/cge.12536. PMID 25388820. S2CID 26414866.
Bruenderman EH, Martin RC (March 2015). "High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening". The Journal of Surgical Research. 194 (1): 212–9. doi:10.1016/j.jss.2014.06.046. PMC 4559279. PMID 25479908.
Subar D, Gobardhan PD, Gayet B (February 2014). "Laparoscopic pancreatic surgery: An overview of the literature and experiences of a single center". Best Practice & Research. Clinical Gastroenterology. 28 (1): 123–32. doi:10.1016/j.bpg.2013.11.011. PMID 24485260.
Weiss MJ, Wolfgang CL (2013). "Irreversible electroporation: a novel pancreatic cancer therapy". Current Problems in Cancer. 37 (5): 262–5. doi:10.1016/j.currproblcancer.2013.10.002. PMID 24331180. S2CID 3137300.
Moir J, White SA, French JJ, Littler P, Manas DM (December 2014). "Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer". European Journal of Surgical Oncology. 40 (12): 1598–604. doi:10.1016/j.ejso.2014.08.480. PMID 25307210.
Kleger A, Perkhofer L, Seufferlein T (July 2014). "Smarter drugs emerging in pancreatic cancer therapy". Annals of Oncology. 25 (7): 1260–1270. doi:10.1093/annonc/mdu013. PMID 24631947.
Tang SC, Chen YC (August 2014). "Novel therapeutic targets for pancreatic cancer". World Journal of Gastroenterology. 20 (31): 10825–44. doi:10.3748/wjg.v20.i31.10825. PMC 4138462. PMID 25152585.
Rossi ML, Rehman AA, Gondi CS (August 2014). "Therapeutic options for the management of pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11142–59. doi:10.3748/wjg.v20.i32.11142. PMC 4145755. PMID 25170201.
Farhangnia P (4 June 2024). "Current and future immunotherapeutic approaches in pancreatic cancer treatment". Journal of Hematology & Oncology. 17 (1): 40. doi:10.1186/s13045-024-01561-6. PMC 11151541. PMID 38835055.
Ady JW, Heffner J, Klein E, Fong Y (2014). "Oncolytic viral therapy for pancreatic cancer: current research and future directions". Oncolytic Virotherapy. 3: 35–46. doi:10.2147/OV.S53858. PMC 4918362. PMID 27512661.
Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. (July 2018). "Tumor microenvironment participates in metastasis of pancreatic cancer". Molecular Cancer. 17 (1): 108. doi:10.1186/s12943-018-0858-1. PMC 6065152. PMID 30060755.
Das SS, Dubey AK, Singh N, Verma PR, Singh SK, Singh SK (9 January 2023). "Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles". In Rahman M, Almalki HW, Alrobaian M, Beg S, Alharbi KS (eds.). Hormone Related Cancer Mechanistic and Nanomedicines. Singapore: Springer. pp. 149–168. doi:10.1007/978-981-19-5558-7_8. ISBN 978-981-19-5557-0.

europac-org.eu

"About EUROPAC". European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). University of Liverpool. Archived from the original on 26 July 2014. Retrieved 17 July 2014.

handle.net

hdl.handle.net

Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, et al. (August 2014). "Peptide receptor radionuclide therapy for advanced neuroendocrine tumors". Thoracic Surgery Clinics. 24 (3): 333–49. doi:10.1016/j.thorsurg.2014.04.005. hdl:11392/2378236. PMID 25065935.

harvard.edu

ui.adsabs.harvard.edu

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. (2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. (November 2012). "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes". Nature. 491 (7424): 399–405. Bibcode:2012Natur.491..399.. doi:10.1038/nature11547. PMC 3530898. PMID 23103869.

jhu.edu

pathology.jhu.edu

"Types of Pancreas Tumors". The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012. Archived from the original on 8 October 2014. Retrieved 18 November 2014.
"Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012. Archived from the original on 5 January 2015. Retrieved 5 January 2015.

lwwoncology.com

Zyromski NJ, Nakeeb A, Lillemoe KD (2010). "Chapter 35: Cancer of the Pancreas: Surgical Management". In Silberman H, Silberman AW (eds.). Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems (online ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. ISBN 978-0-7817-6546-6. Archived from the original on 6 February 2015. Retrieved 3 November 2014.

medscape.com

Mulcahy N (17 December 2014). "FDA Approves Lanreotide for Neuroendocrine Tumors". Medscape Medical News. WebMD LLC. Archived from the original on 18 January 2015. Retrieved 25 December 2014.

nature.com

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. (19 February 2025). "RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer". Nature: 1–10. doi:10.1038/s41586-024-08508-4. ISSN 1476-4687.

nbcnews.com

"mRNA vaccines show promise in pancreatic cancer in early trial". NBC News. 19 February 2025. Retrieved 21 February 2025.

nccn.org

"Neuroendocrine tumors, NCCN Guidelines Version 1.2015" (PDF). National Comprehensive Cancer Network, Inc. NCCN). 11 November 2014. Retrieved 25 December 2014.
"Pancreatic adenocarcinoma. NCCN Guidelines Version 1.2015" (PDF). NCCN Guidelines. National Comprehensive Cancer Network, Inc. 4 December 2014. Retrieved 26 December 2014.

nhs.uk

"Causes of pancreatic cancer". NHS Choices. National Health Service, England. 7 October 2014. Archived from the original on 6 November 2014. Retrieved 5 December 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ryan DP, Hong TS, Bardeesy N (September 2014). "Pancreatic adenocarcinoma". The New England Journal of Medicine. 371 (11): 1039–49. doi:10.1056/NEJMra1404198. PMID 25207767.
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. (September 2013). "Recent progress in pancreatic cancer". CA: A Cancer Journal for Clinicians. 63 (5): 318–48. doi:10.3322/caac.21190. PMC 3769458. PMID 23856911.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer" (PDF). Lancet. 378 (9791): 607–20. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466. Archived from the original (PDF) on 12 January 2015.
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Unless otherwise specified in boxes, reference is: Pishvaian MJ, Brody JR (March 2017). "Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159–66, 168. PMID 28299752.
Bond-Smith G, Banga N, Hammond TM, Imber CJ (May 2012). "Pancreatic adenocarcinoma". BMJ. 344 (may16 1): e2476. doi:10.1136/bmj.e2476. PMID 22592847. S2CID 206894869.
Amri F, Belkhayat C, Yeznasni A, Koulali H, Jabi R, Zazour A, et al. (September 2023). "Association between pancreatic cancer and diabetes: insights from a retrospective cohort study". BMC Cancer. 23 (1): 856. doi:10.1186/s12885-023-11344-w. PMC 10496157. PMID 37697301.
Sun Y, He X, Sun Y (27 September 2023). "Red and processed meat and pancreatic cancer risk: a meta-analysis". Frontiers in Nutrition. 10: 1249407. doi:10.3389/fnut.2023.1249407. PMC 10565855. PMID 37829734.
Larsson SC, Wolk A (January 2012). "Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies". British Journal of Cancer. 106 (3): 603–607. doi:10.1038/bjc.2011.585. PMC 3273353. PMID 22240790.
Rohrmann S, Linseisen J, Nöthlings U, Overvad K, Egeberg R, Tjønneland A, et al. (February 2013). "Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition". International Journal of Cancer. 132 (3): 617–624. doi:10.1002/ijc.27637. PMID 22610753. S2CID 2613568.
Bardou M, Le Ray I (December 2013). "Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies". Best Practice & Research. Clinical Gastroenterology. 27 (6): 881–892. doi:10.1016/j.bpg.2013.09.006. PMID 24182608.
Wang Y, Miller FH, Chen ZE, Merrick L, Mortele KJ, Hoff FL, et al. (2011). "Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas". Radiographics. 31 (3): E47 – E64. doi:10.1148/rg.313105174. PMID 21721197.
Öberg K, Knigge U, Kwekkeboom D, Perren A, et al. (ESMO Guidelines Working Group) (October 2012). "Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii124 – vii130. doi:10.1093/annonc/mds295. PMID 22997445. (Table 5 outlines the proposed TNM staging system for PanNETs.)
Farrell JJ, Fernández-del Castillo C (June 2013). "Pancreatic cystic neoplasms: management and unanswered questions". Gastroenterology. 144 (6): 1303–15. doi:10.1053/j.gastro.2013.01.073. PMID 23622140.
The PanNET denomination is in line with WHO guidelines for the classification of tumors of the digestive system "WHO classification of tumours of the digestive system – NLM Catalog – NCBI". Archived from the original on 9 September 2017. Retrieved 7 September 2017. published in 2010. Historically, PanNETs have also been referred to by a variety of terms, and are still commonly called "pancreatic endocrine tumors". See: Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–12. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
De La Cruz MS, Young AP, Ruffin MT (April 2014). "Diagnosis and management of pancreatic cancer". American Family Physician. 89 (8): 626–32. PMID 24784121.
Pannala R, Basu A, Petersen GM, Chari ST (January 2009). "New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer". The Lancet. Oncology. 10 (1): 88–95. doi:10.1016/S1470-2045(08)70337-1. PMC 2795483. PMID 19111249.
Sperti C, Moletta L, Patanè G (October 2014). "Metastatic tumors to the pancreas: The role of surgery". World Journal of Gastrointestinal Oncology. 6 (10): 381–92. doi:10.4251/wjgo.v6.i10.381. PMC 4197429. PMID 25320654.
Anderson LN, Cotterchio M, Gallinger S (August 2009). "Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada". Cancer Causes & Control. 20 (6): 825–834. doi:10.1007/s10552-009-9303-5. PMC 3907069. PMID 19194662.
Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. (July 2012). "Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)". Annals of Oncology. 23 (7): 1880–88. doi:10.1093/annonc/mdr541. PMC 3387822. PMID 22104574.
De Rubeis V, Cotterchio M, Smith BT, Griffith LE, Borgida A, Gallinger S, et al. (September 2019). "Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada". Cancer Causes & Control. 30 (9): 955–966. doi:10.1007/s10552-019-01197-9. PMC 6685923. PMID 31230151.
Peters ML, Tseng JF, Miksad RA (July 2016). "Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment". Clinical Therapeutics. 38 (7): 1622–35. doi:10.1016/j.clinthera.2016.03.006. PMID 27041411.
Reznik R, Hendifar AE, Tuli R (2014). "Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma". Frontiers in Physiology. 5: 87. doi:10.3389/fphys.2014.00087. PMC 3939680. PMID 24624093.
Greenhalf W, Grocock C, Harcus M, Neoptolemos J (May 2009). "Screening of high-risk families for pancreatic cancer". Pancreatology. 9 (3): 215–22. doi:10.1159/000210262. PMID 19349734. S2CID 29100310.
Venturi S (August 2021). "Cesium in Biology, Pancreatic Cancer, and Controversy in High and Low Radiation Exposure Damage-Scientific, Environmental, Geopolitical, and Economic Aspects". International Journal of Environmental Research and Public Health. 18 (17): 8934. doi:10.3390/ijerph18178934. PMC 8431133. PMID 34501532. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Pericleous M, Rossi RE, Mandair D, Whyand T, Caplin ME (January 2014). "Nutrition and pancreatic cancer". Anticancer Research. 34 (1): 9–21. PMID 24403441.
Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA (June 2016). "Surgical and molecular pathology of pancreatic neoplasms". Diagnostic Pathology. 11 (1): 47. doi:10.1186/s13000-016-0497-z. PMC 4897815. PMID 27267993. (distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)), Image title and optimization: Mikael Häggström, M.D.
Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, et al. (March 2011). "Genetic and epigenetic alterations in pancreatic carcinogenesis". Current Genomics. 12 (1): 15–24. doi:10.2174/138920211794520132. PMC 3129039. PMID 21886451.
Rooney SL, Shi J (October 2016). "Intraductal Tubulopapillary Neoplasm of the Pancreas: An Update From a Pathologist's Perspective". Archives of Pathology & Laboratory Medicine. 140 (10): 1068–73. doi:10.5858/arpa.2016-0207-RA. PMID 27684978.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. (August 2017). "A pathology atlas of the human cancer transcriptome". Science. 357 (6352): eaan2507. doi:10.1126/science.aan2507. PMID 28818916.
Park W, Chawla A, O'Reilly EM (7 September 2021). "Pancreatic Cancer: A Review". JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027. PMC 9363152. PMID 34547082.
Lewis MA, Yao JC (February 2014). "Molecular pathology and genetics of gastrointestinal neuroendocrine tumours". Current Opinion in Endocrinology, Diabetes and Obesity. 21 (1): 22–27. doi:10.1097/MED.0000000000000033. PMID 24310147. S2CID 31094880.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. (September 2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". The Journal of Clinical Endocrinology and Metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327.
Fitzgerald JE, White MJ, Lobo DN (April 2009). "Courvoisier's gallbladder: law or sign?". World Journal of Surgery. 33 (4): 886–91. doi:10.1007/s00268-008-9908-y. PMID 19190960. S2CID 21799234.
Piraka C, Scheiman JM (September 2011). "New diagnostic imaging modalities for pancreatic disease". Current Opinion in Gastroenterology. 27 (5): 475–80. doi:10.1097/MOG.0b013e328349e30c. PMID 21743318. S2CID 38963685.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P (October 2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii33–40. doi:10.1093/annonc/mds224. PMID 22997452.
Skafida E, Grammatoglou X, Glava C, Zissis D, Paschalidis N, Katsamagkou E, et al. (February 2010). "Adenosquamous carcinoma of the pancreas: a case report". Cases Journal. 3 (1): 41. doi:10.1186/1757-1626-3-41. PMC 2825199. PMID 20205828.
Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. (January 2016). "Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting". Annals of Surgery. 263 (1): 162–77. doi:10.1097/SLA.0000000000001173. PMC 4568174. PMID 25775066.
Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas Jr J (2017). "KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer". Cancers. 9 (5): 3956–3972. doi:10.3390/cancers9050042. PMC 5448143. PMID 28471481.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Cascinu S, Falconi M, Valentini V, Jelic S (May 2010). "Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 21 (Supplement 5): v55–58. doi:10.1093/annonc/mdq165. PMID 20555103.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (August 2019). "Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement". JAMA. 322 (5): 438–44. doi:10.1001/jama.2019.10232. PMID 31386141.
He XY, Yuan YZ (August 2014). "Advances in pancreatic cancer research: moving towards early detection". World Journal of Gastroenterology. 20 (32): 11241–48. doi:10.3748/wjg.v20.i32.11241. PMC 4145762. PMID 25170208.
Okano K, Suzuki Y (August 2014). "Strategies for early detection of resectable pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11230–40. doi:10.3748/wjg.v20.i32.11230. PMC 4145761. PMID 25170207.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. (January 2020). "Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium". Gut. 69 (1): 7–17. doi:10.1136/gutjnl-2019-319352. PMC 7295005. PMID 31672839.
Sun J, Li Y, Liu L, Jiang Z, Liu G (December 2019). "Aspirin use and pancreatic cancer risk: A systematic review of observational studies". Medicine. 98 (51): e18033. doi:10.1097/MD.0000000000018033. PMC 6940047. PMID 31860953.
Gurusamy KS, Kumar S, Davidson BR, Fusai G (February 2014). "Resection versus other treatments for locally advanced pancreatic cancer". The Cochrane Database of Systematic Reviews. 2014 (2): CD010244. doi:10.1002/14651858.CD010244.pub2. PMC 11095847. PMID 24578248.
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, et al. (December 2011). "Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis". Annals of Surgery. 254 (6): 882–93. doi:10.1097/SLA.0b013e31823ac299. PMID 22064622. S2CID 42685174.
Alamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, et al. (October 2014). "Improving outcomes in pancreatic cancer: key points in perioperative management". World Journal of Gastroenterology. 20 (39): 14237–45. doi:10.3748/wjg.v20.i39.14237. PMC 4202352. PMID 25339810.
Lopez NE, Prendergast C, Lowy AM (August 2014). "Borderline resectable pancreatic cancer: definitions and management". World Journal of Gastroenterology. 20 (31): 10740–51. doi:10.3748/wjg.v20.i31.10740. PMC 4138454. PMID 25152577.
Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M (July 2014). "Neoadjuvant strategies for pancreatic cancer". World Journal of Gastroenterology. 20 (28): 9374–83. doi:10.3748/wjg.v20.i28.9374 (inactive 1 November 2024). PMC 4110569. PMID 25071332.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (April 2010). "Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages". PLOS Medicine. 7 (4): e1000267. doi:10.1371/journal.pmed.1000267. PMC 2857873. PMID 20422030.
Christians KK, Evans DB (June 2015). "Additional support for neoadjuvant therapy in the management of pancreatic cancer". Annals of Surgical Oncology. 22 (6): 1755–58. doi:10.1245/s10434-014-4307-0. PMID 25519932.
Tsvetkova EV, Asmis TR (August 2014). "Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?". Current Oncology. 21 (4): e650–7. doi:10.3747/co.21.2006. PMC 4117630. PMID 25089113.
Zhan HX, Xu JW, Wu D, Zhang TP, Hu SY (February 2015). "Pancreatic cancer stem cells: new insight into a stubborn disease". Cancer Letters. 357 (2): 429–37. doi:10.1016/j.canlet.2014.12.004. PMID 25499079.
Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, et al. (August 2014). "Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics". World Journal of Gastroenterology. 20 (31): 10790–801. doi:10.3748/wjg.v20.i31.10790. PMC 4138459. PMID 25152582.
Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR (July 2016). "Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer". The Cochrane Database of Systematic Reviews. 2016 (7): CD009323. doi:10.1002/14651858.CD009323.pub3. PMC 6458011. PMID 27383694.
Heinemann V, Haas M, Boeck S (October 2013). "Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer". Annals of Oncology. 24 (10): 2484–92. doi:10.1093/annonc/mdt239. PMID 23852311.
Thota R, Pauff JM, Berlin JD (January 2014). "Treatment of metastatic pancreatic adenocarcinoma: a review". Oncology. 28 (1): 70–74. PMID 24683721.
Borazanci E, Von Hoff DD (September 2014). "Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer". Expert Review of Gastroenterology & Hepatology. 8 (7): 739–47. doi:10.1586/17474124.2014.925799. PMID 24882381. S2CID 31633898.
Haggstrom L, Chan WY, Nagrial A, Chantrill LA, Sim HW, Yip D, et al. (5 December 2024). "Chemotherapy and radiotherapy for advanced pancreatic cancer". The Cochrane Database of Systematic Reviews. 12 (12:CD011044). John Wiley & Sons, Ltd.: Abstract. doi:10.1002/14651858.CD011044.pub3. PMC 11619003. PMID 39635901.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. (November 2001). "Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial". Lancet. 358 (9293): 1576–1585. doi:10.1016/S0140-6736(01)06651-X. PMID 11716884. S2CID 23803289.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. (March 2004). "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer". The New England Journal of Medicine. 350 (12): 1200–1210. doi:10.1056/NEJMoa032295. PMID 15028824.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. (2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors". Neuroendocrinology. 95 (2): 120–34. doi:10.1159/000335587. PMID 22261872. S2CID 6985904.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. (2012). "ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary". Neuroendocrinology. 95 (2): 157–76. doi:10.1159/000335597. PMID 22262022. S2CID 2097604.
Rossi RE, Massironi S, Conte D, Peracchi M (January 2014). "Therapy for metastatic pancreatic neuroendocrine tumors". Annals of Translational Medicine. 2 (1): 8. doi:10.3978/j.issn.2305-5839.2013.03.01. PMC 4200651. PMID 25332984.
Gulenchyn KY, Yao X, Asa SL, Singh S, Law C (May 2012). "Radionuclide therapy in neuroendocrine tumours: a systematic review". Clinical Oncology. 24 (4): 294–308. doi:10.1016/j.clon.2011.12.003. PMID 22221516.
Vinik AI (November 2014). "Advances in diagnosis and treatment of pancreatic neuroendocrine tumors". Endocrine Practice. 20 (11): 1222–30. doi:10.4158/EP14373.RA. PMID 25297671.
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. (March 2010). "Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors". Seminars in Nuclear Medicine. 40 (2): 78–88. doi:10.1053/j.semnuclmed.2009.10.004. PMID 20113677.
Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, et al. (August 2014). "Peptide receptor radionuclide therapy for advanced neuroendocrine tumors". Thoracic Surgery Clinics. 24 (3): 333–49. doi:10.1016/j.thorsurg.2014.04.005. hdl:11392/2378236. PMID 25065935.
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, et al. (June 2015). "Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors". Cancer Chemotherapy and Pharmacology. 75 (6): 1099–114. doi:10.1007/s00280-014-2642-2. PMID 25480314. S2CID 39434924.
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, et al. (August 2015). "Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group". Annals of Surgical Oncology. 22 (8): 2685–99. doi:10.1245/s10434-014-4145-0. PMID 25366583. S2CID 8129133.
Buanes TA (August 2014). "Pancreatic cancer-improved care achievable". World Journal of Gastroenterology. 20 (30): 10405–18. doi:10.3748/wjg.v20.i30.10405. PMC 4130847. PMID 25132756.
Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA (March 2011). Arcidiacono PG (ed.). "Celiac plexus block for pancreatic cancer pain in adults". The Cochrane Database of Systematic Reviews. 2019 (3): CD007519. doi:10.1002/14651858.CD007519.pub2. PMC 6464722. PMID 21412903.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007). "Cancer statistics, 2007". CA: A Cancer Journal for Clinicians. 57 (1): 43–66. doi:10.3322/canjclin.57.1.43. PMID 17237035. S2CID 22305510.
Busnardo AC, DiDio LJ, Tidrick RT, Thomford NR (November 1983). "History of the pancreas". American Journal of Surgery. 146 (5): 539–50. doi:10.1016/0002-9610(83)90286-6. PMID 6356946.
Are C, Dhir M, Ravipati L (June 2011). "History of pancreaticoduodenectomy: early misconceptions, initial milestones and the pioneers". HPB. 13 (6): 377–84. doi:10.1111/j.1477-2574.2011.00305.x. PMC 3103093. PMID 21609369.
Cameron JL, Riall TS, Coleman J, Belcher KA (July 2006). "One thousand consecutive pancreaticoduodenectomies". Annals of Surgery. 244 (1): 10–5. doi:10.1097/01.sla.0000217673.04165.ea. PMC 1570590. PMID 16794383.
Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, et al. (September 2012). "Evolution of the Whipple procedure at the Massachusetts General Hospital". Surgery. 152 (3 Suppl 1): S56-63. doi:10.1016/j.surg.2012.05.022. PMC 3806095. PMID 22770961.
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. (November 2012). "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes". Nature. 491 (7424): 399–405. Bibcode:2012Natur.491..399.. doi:10.1038/nature11547. PMC 3530898. PMID 23103869.
Feng HY, Chen YC (September 2016). "Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective". World Journal of Gastroenterology. 22 (33): 7463–7477. doi:10.3748/wjg.v22.i33.7463. PMC 5011662. PMID 27672269.
Sharma B, Twelker K, Nguyen C, Ellis S, Bhatia ND, Kuschner Z, et al. (June 2024). "Bile Acids in Pancreatic Carcinogenesis". Metabolites. 14 (7): 348. doi:10.3390/metabo14070348. PMC 11278541. PMID 39057671.
Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV (September 2015). "Pancreatic cancer genomics: where can the science take us?". Clinical Genetics. 88 (3): 213–9. doi:10.1111/cge.12536. PMID 25388820. S2CID 26414866.
Bruenderman EH, Martin RC (March 2015). "High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening". The Journal of Surgical Research. 194 (1): 212–9. doi:10.1016/j.jss.2014.06.046. PMC 4559279. PMID 25479908.
Subar D, Gobardhan PD, Gayet B (February 2014). "Laparoscopic pancreatic surgery: An overview of the literature and experiences of a single center". Best Practice & Research. Clinical Gastroenterology. 28 (1): 123–32. doi:10.1016/j.bpg.2013.11.011. PMID 24485260.
Weiss MJ, Wolfgang CL (2013). "Irreversible electroporation: a novel pancreatic cancer therapy". Current Problems in Cancer. 37 (5): 262–5. doi:10.1016/j.currproblcancer.2013.10.002. PMID 24331180. S2CID 3137300.
Moir J, White SA, French JJ, Littler P, Manas DM (December 2014). "Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer". European Journal of Surgical Oncology. 40 (12): 1598–604. doi:10.1016/j.ejso.2014.08.480. PMID 25307210.
Kleger A, Perkhofer L, Seufferlein T (July 2014). "Smarter drugs emerging in pancreatic cancer therapy". Annals of Oncology. 25 (7): 1260–1270. doi:10.1093/annonc/mdu013. PMID 24631947.
Tang SC, Chen YC (August 2014). "Novel therapeutic targets for pancreatic cancer". World Journal of Gastroenterology. 20 (31): 10825–44. doi:10.3748/wjg.v20.i31.10825. PMC 4138462. PMID 25152585.
Rossi ML, Rehman AA, Gondi CS (August 2014). "Therapeutic options for the management of pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11142–59. doi:10.3748/wjg.v20.i32.11142. PMC 4145755. PMID 25170201.
Farhangnia P (4 June 2024). "Current and future immunotherapeutic approaches in pancreatic cancer treatment". Journal of Hematology & Oncology. 17 (1): 40. doi:10.1186/s13045-024-01561-6. PMC 11151541. PMID 38835055.
Ady JW, Heffner J, Klein E, Fong Y (2014). "Oncolytic viral therapy for pancreatic cancer: current research and future directions". Oncolytic Virotherapy. 3: 35–46. doi:10.2147/OV.S53858. PMC 4918362. PMID 27512661.
Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. (July 2018). "Tumor microenvironment participates in metastasis of pancreatic cancer". Molecular Cancer. 17 (1): 108. doi:10.1186/s12943-018-0858-1. PMC 6065152. PMID 30060755.

ncbi.nlm.nih.gov

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. (September 2013). "Recent progress in pancreatic cancer". CA: A Cancer Journal for Clinicians. 63 (5): 318–48. doi:10.3322/caac.21190. PMC 3769458. PMID 23856911.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer" (PDF). Lancet. 378 (9791): 607–20. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466. Archived from the original (PDF) on 12 January 2015.
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Amri F, Belkhayat C, Yeznasni A, Koulali H, Jabi R, Zazour A, et al. (September 2023). "Association between pancreatic cancer and diabetes: insights from a retrospective cohort study". BMC Cancer. 23 (1): 856. doi:10.1186/s12885-023-11344-w. PMC 10496157. PMID 37697301.
Sun Y, He X, Sun Y (27 September 2023). "Red and processed meat and pancreatic cancer risk: a meta-analysis". Frontiers in Nutrition. 10: 1249407. doi:10.3389/fnut.2023.1249407. PMC 10565855. PMID 37829734.
Larsson SC, Wolk A (January 2012). "Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies". British Journal of Cancer. 106 (3): 603–607. doi:10.1038/bjc.2011.585. PMC 3273353. PMID 22240790.
The PanNET denomination is in line with WHO guidelines for the classification of tumors of the digestive system "WHO classification of tumours of the digestive system – NLM Catalog – NCBI". Archived from the original on 9 September 2017. Retrieved 7 September 2017. published in 2010. Historically, PanNETs have also been referred to by a variety of terms, and are still commonly called "pancreatic endocrine tumors". See: Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–12. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Pannala R, Basu A, Petersen GM, Chari ST (January 2009). "New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer". The Lancet. Oncology. 10 (1): 88–95. doi:10.1016/S1470-2045(08)70337-1. PMC 2795483. PMID 19111249.
Sperti C, Moletta L, Patanè G (October 2014). "Metastatic tumors to the pancreas: The role of surgery". World Journal of Gastrointestinal Oncology. 6 (10): 381–92. doi:10.4251/wjgo.v6.i10.381. PMC 4197429. PMID 25320654.
Anderson LN, Cotterchio M, Gallinger S (August 2009). "Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada". Cancer Causes & Control. 20 (6): 825–834. doi:10.1007/s10552-009-9303-5. PMC 3907069. PMID 19194662.
Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. (July 2012). "Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)". Annals of Oncology. 23 (7): 1880–88. doi:10.1093/annonc/mdr541. PMC 3387822. PMID 22104574.
De Rubeis V, Cotterchio M, Smith BT, Griffith LE, Borgida A, Gallinger S, et al. (September 2019). "Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada". Cancer Causes & Control. 30 (9): 955–966. doi:10.1007/s10552-019-01197-9. PMC 6685923. PMID 31230151.
Reznik R, Hendifar AE, Tuli R (2014). "Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma". Frontiers in Physiology. 5: 87. doi:10.3389/fphys.2014.00087. PMC 3939680. PMID 24624093.
Venturi S (August 2021). "Cesium in Biology, Pancreatic Cancer, and Controversy in High and Low Radiation Exposure Damage-Scientific, Environmental, Geopolitical, and Economic Aspects". International Journal of Environmental Research and Public Health. 18 (17): 8934. doi:10.3390/ijerph18178934. PMC 8431133. PMID 34501532. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA (June 2016). "Surgical and molecular pathology of pancreatic neoplasms". Diagnostic Pathology. 11 (1): 47. doi:10.1186/s13000-016-0497-z. PMC 4897815. PMID 27267993. (distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)), Image title and optimization: Mikael Häggström, M.D.
Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, et al. (March 2011). "Genetic and epigenetic alterations in pancreatic carcinogenesis". Current Genomics. 12 (1): 15–24. doi:10.2174/138920211794520132. PMC 3129039. PMID 21886451.
Park W, Chawla A, O'Reilly EM (7 September 2021). "Pancreatic Cancer: A Review". JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027. PMC 9363152. PMID 34547082.
Skafida E, Grammatoglou X, Glava C, Zissis D, Paschalidis N, Katsamagkou E, et al. (February 2010). "Adenosquamous carcinoma of the pancreas: a case report". Cases Journal. 3 (1): 41. doi:10.1186/1757-1626-3-41. PMC 2825199. PMID 20205828.
Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. (January 2016). "Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting". Annals of Surgery. 263 (1): 162–77. doi:10.1097/SLA.0000000000001173. PMC 4568174. PMID 25775066.
Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas Jr J (2017). "KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer". Cancers. 9 (5): 3956–3972. doi:10.3390/cancers9050042. PMC 5448143. PMID 28471481.{{cite journal}}: CS1 maint: multiple names: authors list (link)
He XY, Yuan YZ (August 2014). "Advances in pancreatic cancer research: moving towards early detection". World Journal of Gastroenterology. 20 (32): 11241–48. doi:10.3748/wjg.v20.i32.11241. PMC 4145762. PMID 25170208.
Okano K, Suzuki Y (August 2014). "Strategies for early detection of resectable pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11230–40. doi:10.3748/wjg.v20.i32.11230. PMC 4145761. PMID 25170207.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. (January 2020). "Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium". Gut. 69 (1): 7–17. doi:10.1136/gutjnl-2019-319352. PMC 7295005. PMID 31672839.
Sun J, Li Y, Liu L, Jiang Z, Liu G (December 2019). "Aspirin use and pancreatic cancer risk: A systematic review of observational studies". Medicine. 98 (51): e18033. doi:10.1097/MD.0000000000018033. PMC 6940047. PMID 31860953.
Gurusamy KS, Kumar S, Davidson BR, Fusai G (February 2014). "Resection versus other treatments for locally advanced pancreatic cancer". The Cochrane Database of Systematic Reviews. 2014 (2): CD010244. doi:10.1002/14651858.CD010244.pub2. PMC 11095847. PMID 24578248.
Alamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, et al. (October 2014). "Improving outcomes in pancreatic cancer: key points in perioperative management". World Journal of Gastroenterology. 20 (39): 14237–45. doi:10.3748/wjg.v20.i39.14237. PMC 4202352. PMID 25339810.
Lopez NE, Prendergast C, Lowy AM (August 2014). "Borderline resectable pancreatic cancer: definitions and management". World Journal of Gastroenterology. 20 (31): 10740–51. doi:10.3748/wjg.v20.i31.10740. PMC 4138454. PMID 25152577.
Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M (July 2014). "Neoadjuvant strategies for pancreatic cancer". World Journal of Gastroenterology. 20 (28): 9374–83. doi:10.3748/wjg.v20.i28.9374 (inactive 1 November 2024). PMC 4110569. PMID 25071332.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (April 2010). "Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages". PLOS Medicine. 7 (4): e1000267. doi:10.1371/journal.pmed.1000267. PMC 2857873. PMID 20422030.
Tsvetkova EV, Asmis TR (August 2014). "Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?". Current Oncology. 21 (4): e650–7. doi:10.3747/co.21.2006. PMC 4117630. PMID 25089113.
Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, et al. (August 2014). "Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics". World Journal of Gastroenterology. 20 (31): 10790–801. doi:10.3748/wjg.v20.i31.10790. PMC 4138459. PMID 25152582.
Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR (July 2016). "Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer". The Cochrane Database of Systematic Reviews. 2016 (7): CD009323. doi:10.1002/14651858.CD009323.pub3. PMC 6458011. PMID 27383694.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. (2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
Rossi RE, Massironi S, Conte D, Peracchi M (January 2014). "Therapy for metastatic pancreatic neuroendocrine tumors". Annals of Translational Medicine. 2 (1): 8. doi:10.3978/j.issn.2305-5839.2013.03.01. PMC 4200651. PMID 25332984.
Buanes TA (August 2014). "Pancreatic cancer-improved care achievable". World Journal of Gastroenterology. 20 (30): 10405–18. doi:10.3748/wjg.v20.i30.10405. PMC 4130847. PMID 25132756.
Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA (March 2011). Arcidiacono PG (ed.). "Celiac plexus block for pancreatic cancer pain in adults". The Cochrane Database of Systematic Reviews. 2019 (3): CD007519. doi:10.1002/14651858.CD007519.pub2. PMC 6464722. PMID 21412903.
Are C, Dhir M, Ravipati L (June 2011). "History of pancreaticoduodenectomy: early misconceptions, initial milestones and the pioneers". HPB. 13 (6): 377–84. doi:10.1111/j.1477-2574.2011.00305.x. PMC 3103093. PMID 21609369.
Cameron JL, Riall TS, Coleman J, Belcher KA (July 2006). "One thousand consecutive pancreaticoduodenectomies". Annals of Surgery. 244 (1): 10–5. doi:10.1097/01.sla.0000217673.04165.ea. PMC 1570590. PMID 16794383.
Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, et al. (September 2012). "Evolution of the Whipple procedure at the Massachusetts General Hospital". Surgery. 152 (3 Suppl 1): S56-63. doi:10.1016/j.surg.2012.05.022. PMC 3806095. PMID 22770961.
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. (November 2012). "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes". Nature. 491 (7424): 399–405. Bibcode:2012Natur.491..399.. doi:10.1038/nature11547. PMC 3530898. PMID 23103869.
Feng HY, Chen YC (September 2016). "Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective". World Journal of Gastroenterology. 22 (33): 7463–7477. doi:10.3748/wjg.v22.i33.7463. PMC 5011662. PMID 27672269.
Sharma B, Twelker K, Nguyen C, Ellis S, Bhatia ND, Kuschner Z, et al. (June 2024). "Bile Acids in Pancreatic Carcinogenesis". Metabolites. 14 (7): 348. doi:10.3390/metabo14070348. PMC 11278541. PMID 39057671.
Bruenderman EH, Martin RC (March 2015). "High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening". The Journal of Surgical Research. 194 (1): 212–9. doi:10.1016/j.jss.2014.06.046. PMC 4559279. PMID 25479908.
Tang SC, Chen YC (August 2014). "Novel therapeutic targets for pancreatic cancer". World Journal of Gastroenterology. 20 (31): 10825–44. doi:10.3748/wjg.v20.i31.10825. PMC 4138462. PMID 25152585.
Rossi ML, Rehman AA, Gondi CS (August 2014). "Therapeutic options for the management of pancreatic cancer". World Journal of Gastroenterology. 20 (32): 11142–59. doi:10.3748/wjg.v20.i32.11142. PMC 4145755. PMID 25170201.
Farhangnia P (4 June 2024). "Current and future immunotherapeutic approaches in pancreatic cancer treatment". Journal of Hematology & Oncology. 17 (1): 40. doi:10.1186/s13045-024-01561-6. PMC 11151541. PMID 38835055.
Ady JW, Heffner J, Klein E, Fong Y (2014). "Oncolytic viral therapy for pancreatic cancer: current research and future directions". Oncolytic Virotherapy. 3: 35–46. doi:10.2147/OV.S53858. PMC 4918362. PMID 27512661.
Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. (July 2018). "Tumor microenvironment participates in metastasis of pancreatic cancer". Molecular Cancer. 17 (1): 108. doi:10.1186/s12943-018-0858-1. PMC 6065152. PMID 30060755.

nlm.nih.gov

The Medical Subject Headings indexing system refers to "islet cell carcinoma", which is subdivided into gastrinoma, glucagonoma, somatostatinoma, and VIPoma. See: 2014 MeSH tree at "Pancreatic Neoplasms [C04.588.322.475]" Archived 19 March 2016 at the Wayback Machine 16 October 2014

pancan.org

"Five-Year Pancreatic Cancer Survival Rate Increases to 12%". PANCAN. 2023. Archived from the original on 4 March 2023. Retrieved 3 March 2023.

pancreaticcancer.net.au

"Australian Pancreatic Genome Initiative". Garvan Institute. Archived from the original on 26 July 2014. Retrieved 17 July 2014.

pathologyoutlines.com

Image by Mikael Häggström, MD.
Reference for features: Navale P, Savari O, Tomashefski Jr JF, Vyas M. "Solid pseudopapillary neoplasm". Last author update: 4 March 2022
Agostini-Vulaj D. "Pancreas – Exocrine tumors / carcinomas – Intraductal papillary mucinous neoplasm (IPMN)". Pathology Outlines. Topic Completed: 1 July 2018. Revised: 9 March 2020

pcrf.org.uk

"Cancer facts and figures – Why we exist". Pancreatic Cancer Research Fund. Retrieved 5 April 2019.

proteinatlas.org

"The human pathology proteome in pancreatic cancer – The Human Protein Atlas". www.proteinatlas.org. Retrieved 28 September 2017.

semanticscholar.org

api.semanticscholar.org

Bond-Smith G, Banga N, Hammond TM, Imber CJ (May 2012). "Pancreatic adenocarcinoma". BMJ. 344 (may16 1): e2476. doi:10.1136/bmj.e2476. PMID 22592847. S2CID 206894869.
Rohrmann S, Linseisen J, Nöthlings U, Overvad K, Egeberg R, Tjønneland A, et al. (February 2013). "Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition". International Journal of Cancer. 132 (3): 617–624. doi:10.1002/ijc.27637. PMID 22610753. S2CID 2613568.
The PanNET denomination is in line with WHO guidelines for the classification of tumors of the digestive system "WHO classification of tumours of the digestive system – NLM Catalog – NCBI". Archived from the original on 9 September 2017. Retrieved 7 September 2017. published in 2010. Historically, PanNETs have also been referred to by a variety of terms, and are still commonly called "pancreatic endocrine tumors". See: Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–12. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
Greenhalf W, Grocock C, Harcus M, Neoptolemos J (May 2009). "Screening of high-risk families for pancreatic cancer". Pancreatology. 9 (3): 215–22. doi:10.1159/000210262. PMID 19349734. S2CID 29100310.
Lewis MA, Yao JC (February 2014). "Molecular pathology and genetics of gastrointestinal neuroendocrine tumours". Current Opinion in Endocrinology, Diabetes and Obesity. 21 (1): 22–27. doi:10.1097/MED.0000000000000033. PMID 24310147. S2CID 31094880.
Fitzgerald JE, White MJ, Lobo DN (April 2009). "Courvoisier's gallbladder: law or sign?". World Journal of Surgery. 33 (4): 886–91. doi:10.1007/s00268-008-9908-y. PMID 19190960. S2CID 21799234.
Piraka C, Scheiman JM (September 2011). "New diagnostic imaging modalities for pancreatic disease". Current Opinion in Gastroenterology. 27 (5): 475–80. doi:10.1097/MOG.0b013e328349e30c. PMID 21743318. S2CID 38963685.
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, et al. (December 2011). "Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis". Annals of Surgery. 254 (6): 882–93. doi:10.1097/SLA.0b013e31823ac299. PMID 22064622. S2CID 42685174.
Borazanci E, Von Hoff DD (September 2014). "Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer". Expert Review of Gastroenterology & Hepatology. 8 (7): 739–47. doi:10.1586/17474124.2014.925799. PMID 24882381. S2CID 31633898.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. (November 2001). "Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial". Lancet. 358 (9293): 1576–1585. doi:10.1016/S0140-6736(01)06651-X. PMID 11716884. S2CID 23803289.
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors". Neuroendocrinology. 95 (2): 120–34. doi:10.1159/000335587. PMID 22261872. S2CID 6985904.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. (2012). "ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary". Neuroendocrinology. 95 (2): 157–76. doi:10.1159/000335597. PMID 22262022. S2CID 2097604.
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, et al. (June 2015). "Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors". Cancer Chemotherapy and Pharmacology. 75 (6): 1099–114. doi:10.1007/s00280-014-2642-2. PMID 25480314. S2CID 39434924.
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, et al. (August 2015). "Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group". Annals of Surgical Oncology. 22 (8): 2685–99. doi:10.1245/s10434-014-4145-0. PMID 25366583. S2CID 8129133.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007). "Cancer statistics, 2007". CA: A Cancer Journal for Clinicians. 57 (1): 43–66. doi:10.3322/canjclin.57.1.43. PMID 17237035. S2CID 22305510.
Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV (September 2015). "Pancreatic cancer genomics: where can the science take us?". Clinical Genetics. 88 (3): 213–9. doi:10.1111/cge.12536. PMID 25388820. S2CID 26414866.
Weiss MJ, Wolfgang CL (2013). "Irreversible electroporation: a novel pancreatic cancer therapy". Current Problems in Cancer. 37 (5): 262–5. doi:10.1016/j.currproblcancer.2013.10.002. PMID 24331180. S2CID 3137300.

springer.com

link.springer.com

Das SS, Dubey AK, Singh N, Verma PR, Singh SK, Singh SK (9 January 2023). "Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles". In Rahman M, Almalki HW, Alrobaian M, Beg S, Alharbi KS (eds.). Hormone Related Cancer Mechanistic and Nanomedicines. Singapore: Springer. pp. 149–168. doi:10.1007/978-981-19-5558-7_8. ISBN 978-981-19-5557-0.

uptodate.com

Ryan DP (8 July 2014). "Chemotherapy for advanced exocrine pancreatic cancer: Topic 2475, Version 46.0" (subscription required). UpToDate. Wolters Kluwer Health. Archived from the original on 8 December 2014. Retrieved 18 November 2014.

uspreventiveservicestaskforce.org

"Draft Recommendation Statement: Pancreatic Cancer: Screening". US Preventive Services Task Force. Retrieved 11 February 2019.

web.archive.org

"Pancreatic Cancer Treatment (PDQ®) Patient Version". National Cancer Institute. National Institutes of Health. 17 April 2014. Archived from the original on 5 July 2014. Retrieved 8 June 2014.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer" (PDF). Lancet. 378 (9791): 607–20. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466. Archived from the original (PDF) on 12 January 2015.
"Can pancreatic cancer be prevented?". American Cancer Society. 11 June 2014. Archived from the original on 13 November 2014. Retrieved 13 November 2014.
"Five-Year Pancreatic Cancer Survival Rate Increases to 12%". PANCAN. 2023. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
"What Is Cancer? Defining Cancer". National Cancer Institute, National Institutes of Health. 7 March 2014. Archived from the original on 25 June 2014. Retrieved 5 December 2014.
"Pancreatic Cancer Treatment (PDQ®) Health Professional Version". National Cancer Institute. National Institutes of Health. 21 February 2014. Archived from the original on 22 October 2014. Retrieved 24 November 2014. "The highest cure rate occurs if the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. In cases with localized disease and small cancers (<2 cm) with no lymph-node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is still associated with a low actuarial five-year survival rate of 18% to 24%."
Harris RE (2013). "Epidemiology of pancreatic cancer". Epidemiology of Chronic Disease. Jones & Bartlett. pp. 181–190. ISBN 978-0-7637-8047-0. Archived from the original on 24 June 2016.
Handbook of Pancreatic Cancer. New York: Springer. 2009. p. 288. ISBN 978-0-387-77497-8. Archived from the original on 10 September 2017. Retrieved 12 June 2016.
"Types of Pancreas Tumors". The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012. Archived from the original on 8 October 2014. Retrieved 18 November 2014.
The PanNET denomination is in line with WHO guidelines for the classification of tumors of the digestive system "WHO classification of tumours of the digestive system – NLM Catalog – NCBI". Archived from the original on 9 September 2017. Retrieved 7 September 2017. published in 2010. Historically, PanNETs have also been referred to by a variety of terms, and are still commonly called "pancreatic endocrine tumors". See: Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–12. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
The Medical Subject Headings indexing system refers to "islet cell carcinoma", which is subdivided into gastrinoma, glucagonoma, somatostatinoma, and VIPoma. See: 2014 MeSH tree at "Pancreatic Neoplasms [C04.588.322.475]" Archived 19 March 2016 at the Wayback Machine 16 October 2014
"Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. Johns Hopkins Medicine. 2012. Archived from the original on 5 January 2015. Retrieved 5 January 2015.
"Chapter 15; Pancreas" (PDF). Manual for Staging of Cancer (2nd ed.). American Joint Committee on Cancer. pp. 95–98. Archived (PDF) from the original on 29 November 2014. See p. 95 for citation regarding "... lesser degree of involvement of bones and brain and other anatomical sites."
"Causes of pancreatic cancer". NHS Choices. National Health Service, England. 7 October 2014. Archived from the original on 6 November 2014. Retrieved 5 December 2014.
"Cancer Facts and Figures 2014" (PDF). American Cancer Society. Archived (PDF) from the original on 18 December 2014. Retrieved 5 January 2015., p. 19, "Though evidence is still accumulating, consumption of red or processed meat, or meat cooked at very high temperatures, may slightly increase risk."
"Staging of pancreatic cancer". American Cancer Society. 11 June 2014. Archived from the original on 10 August 2020. Retrieved 29 September 2014.
Zyromski NJ, Nakeeb A, Lillemoe KD (2010). "Chapter 35: Cancer of the Pancreas: Surgical Management". In Silberman H, Silberman AW (eds.). Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems (online ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. ISBN 978-0-7817-6546-6. Archived from the original on 6 February 2015. Retrieved 3 November 2014.
National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®) Incidence and Mortality "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version". Archived from the original on 4 January 2015. Retrieved 29 December 2014.
"Diet and activity factors that affect risks for certain cancers: Pancreatic cancer section". American Cancer Society. 20 August 2012. Archived from the original on 4 November 2014. Retrieved 4 November 2014.
Ryan DP (8 July 2014). "Chemotherapy for advanced exocrine pancreatic cancer: Topic 2475, Version 46.0" (subscription required). UpToDate. Wolters Kluwer Health. Archived from the original on 8 December 2014. Retrieved 18 November 2014.
"Cancer Drug Information: FDA Approval for Erlotinib Hydrochloride". National Cancer Institute. National Institutes of Health. 3 July 2013. Archived from the original on 29 November 2014. Retrieved 5 December 2014.
Mulcahy N (17 December 2014). "FDA Approves Lanreotide for Neuroendocrine Tumors". Medscape Medical News. WebMD LLC. Archived from the original on 18 January 2015. Retrieved 25 December 2014.
Everolimus Approved for Pancreatic Neuroendocrine Tumors Archived 16 July 2016 at the Wayback Machine The ASCO Post. 15 May 2011, Volume 2, Issue 8
National Cancer Institute. Cancer Drug Information. FDA Approval for Sunitinib Malate Archived 5 January 2015 at the Wayback Machine. Pancreatic Neuroendocrine Tumors
Text is available electronically (but may require free registration) See: Benson AB, Myerson RJ, Sasson AR (2010). Pancreatic, neuroendocrine GI, and adrenal cancers. Cancer Management: A Multidisciplinary Approach (13th ed.). UBM Medica. ISBN 978-0-615-41824-7. Archived from the original on 15 May 2011.
"Palliative or Supportive Care". American Cancer Society. 2014. Archived from the original on 21 August 2014. Retrieved 20 August 2014.
"If treatment for pancreatic cancer stops working". American Cancer Society. 11 June 2014. Archived from the original on 22 October 2014. Retrieved 20 August 2014.
"Cancer Facts and Figures 2014" (PDF). American Cancer Society. Archived (PDF) from the original on 18 December 2014. Retrieved 5 January 2015., Table, p. 18, rates adjusted for normal life expectancy
"What are the key statistics about pancreatic cancer?". American Cancer Society. 11 June 2014. Archived from the original on 11 November 2014. Retrieved 11 November 2014.
"Pancreatic cancer statistics". Cancer Research UK. Archived from the original on 18 December 2014. Retrieved 18 December 2014.; "In 2010, in the UK, the lifetime risk of developing pancreatic cancer is 1 in 73 for men and 1 in 74 for women", noting "The lifetime risk ... has been calculated ... using the 'Current Probability' method; this is a different method used from most other cancer sites since the possibility of having more than one diagnosis of pancreatic cancer over the course of their lifetime is very low"
"Pancreatic cancer research". Cancer Research UK. Archived from the original on 18 February 2014. Retrieved 17 July 2014.
"Australian Pancreatic Genome Initiative". Garvan Institute. Archived from the original on 26 July 2014. Retrieved 17 July 2014.
"About EUROPAC". European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). University of Liverpool. Archived from the original on 26 July 2014. Retrieved 17 July 2014.

worldcat.org

search.worldcat.org

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. (19 February 2025). "RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer". Nature: 1–10. doi:10.1038/s41586-024-08508-4. ISSN 1476-4687.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. (2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.

zju.edu.cn

m-learning.zju.edu.cn

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer" (PDF). Lancet. 378 (9791): 607–20. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466. Archived from the original (PDF) on 12 January 2015.